1-4 of 4
Terufumi Kato
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)

Akira Sugimoto, Shingo Matsumoto, Hibiki Udagawa, Ryo Itotani, Yuko Usui, Shigeki Umemura, Kazumi Nishino, Ichiro Nakachi, Shoichi Kuyama, Haruko Daga, Satoshi Hara, Shingo Miyamoto, Terufumi Kato, Jun Sakakibara-Konishi, Eriko Tabata, Taku Nakagawa, Tomoya Kawaguchi, Tetsuya Sakai, Yuji Shibata, Hiroki Izumi, Kaname Nosaki, Yoshitaka Zenke, Kiyotaka Yoh, Koichi Goto
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1506–1514.
https://doi.org/10.1158/1078-0432.CCR-22-1749
Published: 14 April 2023
View article titled, A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
Open the PDF for A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid) in another window
Includes: Supplementary data
Journal Articles

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial

Margarita Majem, Jonathan W. Goldman, Thomas John, Christian Grohe, Konstantin Laktionov, Sang-We Kim, Terufumi Kato, Huu Vinh Vu, Shun Lu, Shanqing Li, Kye Young Lee, Charuwan Akewanlop, Chong-Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Domine, Frances A. Shepherd, Shinji Atagi, Lingmin Zeng, Dakshayini Kulkarni, Nenad Medic, Masahiro Tsuboi, Roy S. Herbst, Yi-Long Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2286–2296.
https://doi.org/10.1158/1078-0432.CCR-21-3530
Published: 01 June 2022
View article titled, Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
Open the PDF for Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors

Toshihiko Doi, Kei Muro, Hiroshi Ishii, Terufumi Kato, Takahiro Tsushima, Mitsuhiro Takenoyama, Satoshi Oizumi, Kazuto Gemmoto, Hideaki Suna, Kouki Enokitani, Tetsuyoshi Kawakami, Hiroyoshi Nishikawa, Noboru Yamamoto
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6614–6622.
https://doi.org/10.1158/1078-0432.CCR-19-1090
Published: 15 November 2019
View article titled, A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors
Open the PDF for A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT)

Morihito Okada, Takashi Kijima, Keisuke Aoe, Terufumi Kato, Nobukazu Fujimoto, Kazuhiko Nakagawa, Yuichiro Takeda, Toyoaki Hida, Kuninobu Kanai, Fumio Imamura, Satoshi Oizumi, Toshiaki Takahashi, Mitsuhiro Takenoyama, Hiroshi Tanaka, Jun Hirano, Yoshinobu Namba, Yuichiro Ohe
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (18): 5485–5492.
https://doi.org/10.1158/1078-0432.CCR-19-0103
Published: 13 September 2019
View article titled, Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT)
Open the PDF for Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT) in another window
Includes: Supplementary data